RxDoctor Payments DataLook up a doctor →

Binu Jacob, MD

Clinical Cardiac Electrophysiology · Zephyrhills, FLNPI 1376611681

Payments from drug & device makers

$179,165in general payments, 2019–2025

Across 672 payments — averaging $266.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$67K
  • Boehringer Ingelheim$54K
  • Livanova USA, Inc.$19K
  • Akcea Therapeutics, Inc.$10K
  • Abbott$7K
  • Medtronic$6K
  • plus $17K from 46 others

What the payments were for

  • Travel & lodging$4,06613%
  • Food & beverage$26,68386%
  • Education$4011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,165 in reported general payments places this provider in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$305,923
Medicare patients
953
Services billed
3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban334$379,409
XareltoRivaroxaban121$129,804
EntrestoSacubitril/Valsartan21$24,935
Midodrine Hcl97$7,352
Amiodarone Hcl117$4,384
Metoprolol Succinate356$3,666
Flecainide Acetate60$3,300
Dofetilide11$2,398
Diltiazem 12hr ErDiltiazem Hcl15$1,945
Carvedilol238$1,919
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$1,745
Ranolazine ErRanolazine16$1,681
Nitroglycerin88$1,611
Atorvastatin Calcium224$1,565
Bumetanide39$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$583$379,409334 claims
Johnson & JohnsonXarelto$620$129,804121 claims
NovartisEntresto$486$24,93521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →